Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 162 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HFpEF Clear all
Completed Phase 3 Interventional

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

NCT04916470
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (Semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
54
States / cities
Fairhope, Alabama • Mobile, Alabama • Beverly Hills, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 19, 2026, 5:03 PM EDT
Terminated Not applicable Interventional Results available

Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study

NCT03195660
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction, Sleep Apnea
Interventions
ASV Therapy
Device
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
San Diego, California • Philadelphia, Pennsylvania • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 19, 2026, 5:03 PM EDT
Enrolling by invitation Phase 3 Interventional

Long-Term Open-Label Extension Study of Oral Levosimendan

NCT07436689
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

NCT04327024
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Verinurad, Allopurinol, Placebo for verinurad, Placebo for allopurinol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Granada Hills, California • Northridge, California • Torrance, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 19, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

NCT01951638
View directory record Official record
Conditions
Heart Failure
Interventions
Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 19, 2026, 5:03 PM EDT
Withdrawn Not applicable Interventional

Rivet PVS Therapy in Group 2 PH-HFpEF

NCT05205265
View directory record Official record
Conditions
Heart Failure, Pulmonary Hypertension
Interventions
Rivet Shunt
Device
Lead sponsor
NXT Biomedical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 19, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

BOOST: Blended Onsite and Offsite Structured Exercise Training and Coaching

NCT07413198
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
multi-domain behavioral, coaching, and exercise protocol
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 19, 2026, 5:03 PM EDT
Recruiting No phase listed Observational

WISE CVD - Continuation (WISE HFpEF)

NCT02582021
View directory record Official record
Conditions
Microvascular Coronary Dysfunction, Cardiovascular Disease
Interventions
Coronary Angiography, Coronary Reactivity Testing, Cardiac Magnetic Resonance Imaging, Cardiac Magnetic Resonance Angiography, Computed Coronary Tomographic Angiography, Rest-Stress Millar Testing, Aortic vasorelaxation tests
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 19, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Physiologic Accelerated Pacing as a Treatment in Patients With Heart Failure With Preserved Ejection Fraction

NCT04546555
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
Dual chamber pacemaker, Accelerated Physiologic Pacing, Nocturnal Pacing
Device · Other
Lead sponsor
Daniel L Lustgarten
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 19, 2026, 5:03 PM EDT
Not listed No phase listed Observational

Exercise Capacity Before and After AF Ablation in Patients With HFpEF

NCT05376748
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Atrial Fibrillation
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 110 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 19, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

NCT04592445
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF
Interventions
Greater Splanchnic Nerve Ablation, Sham Control
Device
Lead sponsor
Axon Therapies, Inc.
Industry
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial

NCT02885636
View directory record Official record
Conditions
Congestive Heart Failure, Heart Failure, Left-Sided, Left-Sided Heart Failure
Interventions
Albuterol, Saline placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 19, 2026, 5:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers

NCT03843060
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
AZD9977, Itraconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 19, 2026, 5:03 PM EDT
Recruiting No phase listed Observational

Precision Rehabilitation for Veterans With (HFpEF)

NCT07493915
View directory record Official record
Conditions
Heart Failure, Preserved Ejection Fraction
Interventions
Not listed
Lead sponsor
Columbia VA Health Care System
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 19, 2026, 5:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction

NCT02980068
View directory record Official record
Conditions
Pulmonary; Hypertension, Heart Failure, Preserved Ejection Fraction
Interventions
15N Nitrate, 14N Nitrate
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 19, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

NCT06593314
View directory record Official record
Conditions
Heart Failure, Diabetes
Interventions
Message with EchoGo, Standard Message
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 19, 2026, 5:03 PM EDT
Completed Phase 4 Interventional Results available

BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF

NCT04434664
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Hypertension
Interventions
Amlodipine Besylate, Metoprolol Succinate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 19, 2026, 5:03 PM EDT
Completed Phase 4 Interventional

N-of-1 for Beta-Blockers in Cardiac Amyloidosis

NCT05019027
View directory record Official record
Conditions
Cardiac Amyloidosis, Heart Diseases, TTR Cardiac Amyloidosis
Interventions
Beta blocker
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 19, 2026, 5:03 PM EDT
Active, not recruiting Phase 3 Interventional

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
45
States / cities
Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 5:03 PM EDT
Recruiting Phase 1 Interventional

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT07219511
View directory record Official record
Conditions
Heart, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
VS-041, Placebo
Drug · Other
Lead sponsor
Vasa Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Little Rock, Arkansas • Huntington Beach, California • Santa Maria, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 19, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

PREACTIVE: Preconditioning Exercise Intervention to Improve Symptoms and Quality of Life in Comorbid Atrial Fibrillation and HFpEF

NCT07324772
View directory record Official record
Conditions
Atrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal), Persistent Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
progressive resistance training, combined aerobic + resistance training
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
60 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 19, 2026, 5:03 PM EDT
Recruiting No phase listed Observational

Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF

NCT03876223
View directory record Official record
Conditions
Coronary Microvascular Dysfunction, Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 19, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.

NCT03756285
View directory record Official record
Conditions
Heart Failure
Interventions
AZD4831, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 19, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Effects of Epicatechin on Functional Capacity, Skeletal Muscle Structure and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction (HFPEF)

NCT02068040
View directory record Official record
Conditions
Heart Failure
Interventions
CocoaVia
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 19, 2026, 5:03 PM EDT